Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — Investor Presentation (June 2015)
23 slides from Vivani Medical's investor presentation, Jun 4, 2015
Slide 1: Investor Presentation June 2015
NASDAQ: EYES Investor Presentation June 2015 NASDAQ: EYES
Slide 2: Forward Looking Statements
NASDAQ: EYES Forward Looking Statements This presentation contains certain forward - looking information about Second Sight that is intended to be covered by the safe harbor for "forward - looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward - loo
Slide 3: Second Sight's Technology Platform
NASDAQ: EYES Second Sight’ s Technology Platform • http://www.bloomberg.com/news/videos/2015 - 05 - 21/bionic - eyes - give - second - sight - to - the - blind Second Sight’s Purpose : Restoring vision to the blind Bloomberg Video: Tech that Lets the Blind See 3
Slide 4: Second Sight's Technology Platform (Cont'd)
NASDAQ: EYES Second Sight’ s Technology Platform (Cont’d) https:// www.youtube.com/watch?v=CiyGOUHD2nI Second Sight’s Purpose : Restoring vision to the blind YouTube Video: First Implant at Duke Eye Center 4
Slide 5: Corporate Summary
NASDAQ: EYES Corporate Summary • Restoring vision to the blind with the Argus® II platform technology • Targeting significant addressable market of over 8 million people • Commercial stage – FDA, Canada, EU, & Turkey regulatory approvals • Strong financial position – • Successful IPO in November 201
Slide 6: Significant Addressable Markets
NASDAQ: EYES Significant Addressable Markets 8 million patients globally are legally blind due to unpreventable causes 39 million people worldwide are legally blind 6
Slide 7: The Argus II System – A 25 Year Journey
NASDAQ: EYES Argus II Implant Argus II Glasses Video Processing Unit (VPU) System bypasses dead photoreceptors and stimulates underlying neurons Processes video and transforms into instructions for implant Miniature video camera captures scene Communication to VPU and to implant 1 3 4 2 60 electrode
Slide 8: Experienced Management and Board
NASDAQ: EYES Experienced Management and Board Robert Greenberg Alfred E. Mann President, CEO & Director Chairman & Founder • Co - managed the Alfred E. Mann Foundation • Served as lead reviewer for IDEs and 510(k)s at the Office of Device Evaluation at FDA • Directs MannKind Corporation • Served as
Slide 9: Drivers of Mass Adoption
NASDAQ: EYES Drivers of Mass Adoption R&D Regulatory Environment Reimbursement Centers of Excellence Scalability 9
Slide 10: R&D: Regulatory Milestones
NASDAQ: EYES R&D: Regulatory Milestones AMD Cortical prosthesis Software upgrade 2014 2015 2016 2017 2013 AMD First enrollment in feasibility study AMD Complete enrollment in feasibility AMD First enrollment in pivotal study Cortical First mechanical model animal implants Cortical First complete act
Slide 11: R&D: Software Upgrades
NASDAQ: EYES R&D: Software Upgrades • Controlling the relative stimulation applied to adjacent electrodes can produce spatial patterns of stimulation between electrodes ( virtual electrodes) • Potential resolution enhancement: 10x – 100x at the pixel level • Large body of work to draw upon in cochle
Slide 12: R&D: Expanding into AMD
NASDAQ: EYES R&D: Expanding into AMD • Experimental work conducted in Armand Tanguay Jr.’s lab at USC indicated simulations with retinal prostheses in AMD patients may: • Improve time to grasp a target object and ability to avoid obstacles to grasping a target • Improve functional depth task perform
Slide 13: R&D: Expanding into Direct Cortical Stimulation
NASDAQ: EYES R&D: Expanding into Direct Cortical Stimulation Objective: bypass the optic nerve and directly stimulate the visual cortex Risks Mitigated : • Orion I requires relatively minor modifications to the Argus II device • Direct cortical stimulation to restore vision previously demonstrated b
Slide 14: U.S. Reimbursement Status at Launch
NASDAQ: EYES U.S. Reimbursement Status at Launch • Argus II candidates are Medicare eligible regardless of age due to their disability • In the U.S. many reimbursement objectives have been met: • Billing codes for the device and surgical procedure (CPT, ICD - 9 - CM, HCPCS ) • Transitional pass - th
Slide 15: U.S. Reimbursement Status – June 3, 2015
NASDAQ: EYES U.S. Reimbursement Status – June 3, 2015 • Argus II candidates are Medicare eligible regardless of age due to their disability • In the U.S. many reimbursement objectives have been met: • Billing codes for the device and surgical procedure (CPT, ICD - 9 - CM, HCPCS ) • Transitional pass
Slide 16: European Reimbursement
NASDAQ: EYES European Reimbursement Currently in place In process (24 + months) Not yet sought In process (12 – 24 months) 15
Slide 17: Implanting Centers Worldwide
NASDAQ: EYES North America Kellogg – Univ . Michigan Univ . Southern California Toronto Western Hospital Wills Eye – Philadelphia Duke Eye Center Texas Retina Assoc . – Dallas Bascom Palmer – Univ . Miami Wilmer – Johns Hopkins Emory University Univ . Illinois Chicago Mayo Clinic – Minnesota Retina
Slide 18: Facilities & Manufacturing
NASDAQ: EYES Facilities & Manufacturing • State of the art manufacturing facility located in Sylmar, California • 10,000 square feet of controlled environment rooms (CERs). • Current capacity: ~ 1,200 units / year 10 devices/month • Current manufacturing capacity • Utilizing half the space • Current
Slide 19: Patent Protection
NASDAQ: EYES Patent Protection We solved five very difficult technical problems that to our knowledge no other company has solved. Our patent portfolio contains a large number of claims covering these solutions: Other challenges, 179 grants and applications Reliable long lived miniature electronics
Slide 20: Competitive Landscape
NASDAQ: EYES Competitive Landscape Regulatory Approval Commercialized Limitations CE FDA ✔ ✖ ✖ • Most devices reported to fail within 3 - 9 months post - implant • 8 hour surgical procedure • Requires clear eye optics and cannot be easily adapted to cortical stimulation ✖ ✖ ✖ • Employs optical data
Slide 21: Major Awards & Recognition
NASDAQ: EYES Major Awards & Recognition 20
Slide 22: Investment Highlights
NASDAQ: EYES Investment Highlights • Restoring vision to the blind with the Argus II platform technology • Targeting significant addressable market of over 8 million people • Securing our market leading position with strong patent protection • Ensuring first mover advantage as the only device with U
Slide 23: Investor Relations Contact
NASDAQ: EYES Retail Investor Relations Matt Hayden Chairman MZ North America Direct: 949 - 259 - 4986 Matt.Hayden@mzgroup.us Second Sight Medical Products, Inc. 12744 San Fernando Road Building 3 Sylmar, CA 91342 Direct: 818 - 833 - 5000 www.secondsight.com Institutional Investor Relations Lisa Wils
Second Sight Medical Products — Investor Presentation (June 2015) on 6ix